{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Ambrisentan+5+mg",
    "query": {
      "intervention": "Ambrisentan 5 mg"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 21,
    "total_pages": 3,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Ambrisentan+5+mg&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-10-01T16:18:22.542Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01530464",
      "title": "The Safety Evaluation of Aminophylline and Ambrisentan When Administered Orally Alone and in Combination to Healthy Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "High Altitude Pulmonary Hypertension"
      ],
      "interventions": [
        {
          "name": "Aminophylline",
          "type": "DRUG"
        },
        {
          "name": "Ambrisentan",
          "type": "DRUG"
        },
        {
          "name": "Aminophylline plus ambrisentan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Thies Schroeder",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "18 Years to 40 Years"
      },
      "enrollment_count": 18,
      "start_date": "2012-02",
      "completion_date": "2012-04",
      "has_results": true,
      "last_update_posted_date": "2014-01-16",
      "last_synced_at": "2026-10-01T16:18:22.542Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01530464"
    },
    {
      "nct_id": "NCT00879229",
      "title": "ARTEMIS-PH - Study of Ambrisentan in Subjects With Pulmonary Hypertension Associated With Idiopathic Pulmonary Fibrosis",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Idiopathic Pulmonary Fibrosis",
        "Pulmonary Hypertension"
      ],
      "interventions": [
        {
          "name": "Ambrisentan",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "35 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "35 Years to 80 Years"
      },
      "enrollment_count": 40,
      "start_date": "2009-07",
      "completion_date": "2011-02",
      "has_results": true,
      "last_update_posted_date": "2014-05-15",
      "last_synced_at": "2026-10-01T16:18:22.542Z",
      "location_count": 51,
      "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Davis, California + 40 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Davis",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00879229"
    },
    {
      "nct_id": "NCT01072669",
      "title": "Efficacy of Ambrisentan in Limited Scleroderma Patients in Improving Blood Flow to Hands or Feet",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Ischemia"
      ],
      "interventions": [
        {
          "name": "ambrisentan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Soumya Chatterjee",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 20,
      "start_date": "2010-02",
      "completion_date": "2010-12",
      "has_results": true,
      "last_update_posted_date": "2013-05-03",
      "last_synced_at": "2026-10-01T16:18:22.542Z",
      "location_count": 1,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01072669"
    },
    {
      "nct_id": "NCT01338636",
      "title": "An Open-Label Uncontrolled Study of the Safety and Efficacy of Ambrisentan in Participants With Exercise-Induced Pulmonary Arterial Hypertension (PAH)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Exercise-induced Pulmonary Arterial Hypertension"
      ],
      "interventions": [
        {
          "name": "Ambrisentan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Brigham and Women's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2008-09",
      "completion_date": "2016-05",
      "has_results": true,
      "last_update_posted_date": "2022-01-18",
      "last_synced_at": "2026-10-01T16:18:22.542Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01338636"
    },
    {
      "nct_id": "NCT02936687",
      "title": "Mechanisms of Cerebrovascular Control",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Metabolic Syndrome X"
      ],
      "interventions": [
        {
          "name": "NOS Inhibition",
          "type": "DRUG"
        },
        {
          "name": "ET-1 Inhibition",
          "type": "DRUG"
        },
        {
          "name": "NOS Inhibition Placebo",
          "type": "DRUG"
        },
        {
          "name": "3 Tesla MRI",
          "type": "DEVICE"
        },
        {
          "name": "Intravenous Catheter",
          "type": "DEVICE"
        },
        {
          "name": "Oral Glucose Tolerance Test",
          "type": "OTHER"
        },
        {
          "name": "ET-1 Inhibition Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE",
        "OTHER"
      ],
      "sponsor": "University of Wisconsin, Madison",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 59,
      "start_date": "2017-01-31",
      "completion_date": "2021-09-30",
      "has_results": false,
      "last_update_posted_date": "2021-10-18",
      "last_synced_at": "2026-10-01T16:18:22.542Z",
      "location_count": 1,
      "location_summary": "Madison, Wisconsin",
      "locations": [
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02936687"
    },
    {
      "nct_id": "NCT00851929",
      "title": "Ambrisentan (Letairis) for Sarcoidosis Associated Pulmonary Hypertension",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Sarcoidosis",
        "Pulmonary Hypertension"
      ],
      "interventions": [
        {
          "name": "Ambrisentan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Medical University of South Carolina",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 16,
      "start_date": "2008-11",
      "completion_date": "2011-11",
      "has_results": false,
      "last_update_posted_date": "2018-08-02",
      "last_synced_at": "2026-10-01T16:18:22.542Z",
      "location_count": 2,
      "location_summary": "Chapel Hill, North Carolina • Charleston, South Carolina",
      "locations": [
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        },
        {
          "city": "Charleston",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00851929"
    },
    {
      "nct_id": "NCT01824290",
      "title": "A Study of Tadalafil in Pediatric Participants With Pulmonary Arterial Hypertension (PAH)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hypertension, Pulmonary"
      ],
      "interventions": [
        {
          "name": "Tadalafil",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "ERA as specific PAH treatment",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Months",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "6 Months to 17 Years"
      },
      "enrollment_count": 35,
      "start_date": "2014-02-05",
      "completion_date": "2021-03-10",
      "has_results": true,
      "last_update_posted_date": "2021-11-05",
      "last_synced_at": "2026-10-01T16:18:22.542Z",
      "location_count": 7,
      "location_summary": "Atlanta, Georgia • Detroit, Michigan • Cincinnati, Ohio + 4 more",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01824290"
    },
    {
      "nct_id": "NCT01224210",
      "title": "Ambrisentan in Patients With Porto-pulmonary Hypertension A Multicenter Open Label Trial",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Portopulmonary Hypertension"
      ],
      "interventions": [
        {
          "name": "Ambrisentan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Tufts Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2010-03",
      "completion_date": "2020-03",
      "has_results": true,
      "last_update_posted_date": "2021-01-12",
      "last_synced_at": "2026-10-01T16:18:22.542Z",
      "location_count": 6,
      "location_summary": "La Jolla, California • Jacksonville, Florida • Boston, Massachusetts + 3 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01224210"
    },
    {
      "nct_id": "NCT01093885",
      "title": "Study of Ambrisentan With Antifibrotic Agent Combination Therapy in Diffuse Systemic Sclerosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Systemic Sclerosis",
        "Scleroderma"
      ],
      "interventions": [
        {
          "name": "Ambrisentan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Pennsylvania",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "19 Years to 90 Years"
      },
      "enrollment_count": 15,
      "start_date": "2010-02",
      "completion_date": "2016-07",
      "has_results": true,
      "last_update_posted_date": "2018-11-29",
      "last_synced_at": "2026-10-01T16:18:22.542Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01093885"
    },
    {
      "nct_id": "NCT02169752",
      "title": "Ambrisentan for the Improvement in Right Ventricular Strain in Scleroderma Associated Pulmonary Arterial Hypertension",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Pre-Pulmonary Atrial Hypertension"
      ],
      "interventions": [
        {
          "name": "Ambrisentan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Jewish Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 7,
      "start_date": "2012-09",
      "completion_date": "2017-05-25",
      "has_results": false,
      "last_update_posted_date": "2021-01-19",
      "last_synced_at": "2026-10-01T16:18:22.542Z",
      "location_count": 1,
      "location_summary": "Denver, Colorado",
      "locations": [
        {
          "city": "Denver",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02169752"
    }
  ]
}